These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 18243402)
21. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011 [TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150 [TBL] [Abstract][Full Text] [Related]
23. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609 [TBL] [Abstract][Full Text] [Related]
24. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387 [TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Sakamori Y; Mio T; Mishima M Clin Lung Cancer; 2011 Jan; 12(1):56-61. PubMed ID: 21273181 [TBL] [Abstract][Full Text] [Related]
26. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Sutani A; Nagai Y; Udagawa K; Uchida Y; Koyama N; Murayama Y; Tanaka T; Miyazawa H; Nagata M; Kanazawa M; Hagiwara K; Kobayashi K Br J Cancer; 2006 Dec; 95(11):1483-9. PubMed ID: 17106442 [TBL] [Abstract][Full Text] [Related]
27. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650 [TBL] [Abstract][Full Text] [Related]
28. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. Soh J; Toyooka S; Ichihara S; Fujiwara Y; Hotta K; Suehisa H; Kobayashi N; Ichimura K; Aoe K; Aoe M; Kiura K; Date H Int J Cancer; 2007 Sep; 121(5):1162-7. PubMed ID: 17487844 [TBL] [Abstract][Full Text] [Related]
29. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Kim KS; Jeong JY; Kim YC; Na KJ; Kim YH; Ahn SJ; Baek SM; Park CS; Park CM; Kim YI; Lim SC; Park KO Clin Cancer Res; 2005 Mar; 11(6):2244-51. PubMed ID: 15788673 [TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. Takano T; Ohe Y; Tsuta K; Fukui T; Sakamoto H; Yoshida T; Tateishi U; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Matsuno Y; Furuta K; Tamura T Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5385-90. PubMed ID: 17875767 [TBL] [Abstract][Full Text] [Related]
31. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256 [TBL] [Abstract][Full Text] [Related]
32. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940 [TBL] [Abstract][Full Text] [Related]
33. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624 [TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Endo K; Konishi A; Sasaki H; Takada M; Tanaka H; Okumura M; Kawahara M; Sugiura H; Kuwabara Y; Fukai I; Matsumura A; Yano M; Kobayashi Y; Mizuno K; Haneda H; Suzuki E; Iuchi K; Fujii Y Lung Cancer; 2005 Dec; 50(3):375-84. PubMed ID: 16199108 [TBL] [Abstract][Full Text] [Related]
35. Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib. Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Sakamori Y; Okuda C; Mio T; Mishima M Oncology; 2010; 79(5-6):355-62. PubMed ID: 21430404 [TBL] [Abstract][Full Text] [Related]
36. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114 [TBL] [Abstract][Full Text] [Related]
37. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355 [TBL] [Abstract][Full Text] [Related]
38. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. Yang CH; Yu CJ; Shih JY; Chang YC; Hu FC; Tsai MC; Chen KY; Lin ZZ; Huang CJ; Shun CT; Huang CL; Bean J; Cheng AL; Pao W; Yang PC J Clin Oncol; 2008 Jun; 26(16):2745-53. PubMed ID: 18509184 [TBL] [Abstract][Full Text] [Related]
39. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122 [TBL] [Abstract][Full Text] [Related]
40. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]